The purpose of this study is to assess patient compliance with DuoTrav versus concomitant administration of Timolol 0.5% plus TRAVATAN in patients with open-angle glaucoma or ocular hypertension...
Date First Received: April 23, 2007
Last Updated: April 21, 2008
Verified by: Alcon Research, April 2008
Clinical Trial Phase: Phase 3 | Start Date: March 2007
Overall Status: Recruiting
Estimated Enrollment: 80
Brief Summary
Official Title: “A Phase IIIb Study of DuoTrav to Treat Glaucoma or Ocular Hypertension”
Condition Keyword(s):
Intervention(s):
The purpose of this study is to assess patient compliance with DuoTrav versus concomitant administration of Timolol 0.5% plus TRAVATAN in patients with open-angle glaucoma or ocular hypertension.
Study Type: Interventional
Study Design: Treatment, Randomized, Single Blind, Active Control, Parallel Assignment, Safety/Efficacy Study
Intervention(s) in this Clinical Trial
- Drug: Travoprost/Timolol
Outcome Measures for this Clinical Trial
Primary Measures
- Patient compliance
Criteria for Participation in this Clinical Trial
Inclusion Criteria:
- Adult patients with open-angle glaucoma or ocular hypertension
Exclusion Criteria:
- LogMAR visual acuity worse than 0.60
Gender Eligibility for this Clinical Trial: Both
Minimum Age for this Clinical Trial: 18 Years
Maximum Age for this Clinical Trial: N/A
Are Healthy Volunteers Accepted for this Clinical Trial?: No
Clinical Trial Sponsor Information
Lead Sponsor: Alcon Research
Overall Clinical Trial Officials and Contacts
Theresa Landry Study Director Alcon Research
Overall Contact: Julia White 817-568-6541
Additional Information
Information obtained from ClinicalTrials.gov on October 10, 2008
Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00465803
Study ID Number: C-06-21
ClinicalTrials.gov Identifier: NCT00465803
Health Authority: United States: Food and Drug Administration
Clinical Trials Authorship and Review
Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.
